Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Company Overview - Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment [3] - The company is headquartered in Newton, Massachusetts [3] Product Development - Acumen is advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers [3] - The company is currently conducting a Phase 2 clinical trial named ALTITUDE-AD for early symptomatic Alzheimer's disease patients, following positive results from its Phase 1 trial INTERCEPT-AD [3] Financial Reporting - Acumen Pharmaceuticals will report its first quarter 2025 financial results on May 13, 2025, and will host a conference call and live audio webcast at 8:00 a.m. ET for a business and financial update [1]